
-
Arvinas Inc. NasdaqGS:ARVN Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Location: 5 Science Park, New Haven, CT, 06511, United States | Website: https://www.arvinas.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-396.4M
Cash
954.3M
Avg Qtr Burn
-62.68M
Short % of Float
12.12%
Insider Ownership
6.75%
Institutional Own.
86.58%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vepdegestrant (ARV-471) + Palbociclib Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Phase 3 Data readout | ||
Vepdegestrant + Atirmociclib (1L) Details Solid tumor/s, Cancer, Breast cancer | Phase 3 Initiation | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 2 Data readout | |
ARV-766 +/- Abiraterone Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 1/2 Update | |
Vepdegestrant (ARV-471)+CDK4 inhibitor Details Solid tumor/s, Cancer, Breast cancer | Phase 1/2 Update | |
Vepdegestrant (ARV-471)+CDK7 inhibitor (Samuraciclib) Details Cancer, Solid tumor/s | Phase 1/2 Update | |
Bavdegalutamide (ARV-110) +/- Aabiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s | Phase 1/2 Update | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 1 Data readout | |
ARV-393 Details Cancer, B-cell lymphoma, Blood cancer | Phase 1 Data readout | |
ARV-102 Details Neurodegenerative disease, Parkinson's disease | Phase 1 Data readout |